Active substance
Clarithromycin
- SFDA 44
- US FDA 27
- Health Canada 21
- US price lines 6
- NHS prices 6
- WHO EML 1
- Safety 10
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CLAMYCIN 500 MG TABLET | 500 mg | Film-coated tablet · Oral use | 14 Blister | SAR 63.15 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| CLAREX 500MG TABLET | 500 mg | Film-coated tablet · Oral use | 14 Blister | SAR 51.15 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| CLARIDAR | 250 mg | Film-coated tablet · Oral use | 14 Blister | SAR 24.45 | Generic · Prescription | DAR ALDAWA | Valid |
| CLARIDAR 500 mg film-coated tablet | 500 mg | Film-coated tablet · Oral use | 14 Blister | SAR 41.45 | Generic · Prescription | DAR ALDAWA | Valid |
| CLARIDAR XL 500 mg Tablet | 500 mg | Extended-release tablet · Oral use | 7 Blister | SAR 43.90 | Generic · Prescription | DAR ALDAWA | Valid |
| CLARIDAR XL 500 mg Tablet | 500 mg | Prolonged-release tablet · Oral use | 14 Blister | SAR 57.15 | Generic · Prescription | DAR Al DAWA | Valid |
| CLARIMAC 500 mg film-coated tablet | 500 mg | Film-coated tablet · Oral use | 14 Blister | SAR 54.10 | Generic · Prescription | RIYADH PHARMA | Valid |
| CLARITT 125 MG - 5 ML SUSPENSION | 25 mg/ml | Suspension · Oral use | 1 Bottle | SAR 26.90 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| CLARITT 250 MG - 5 ML SUSPENSION | 50 mg/ml | Suspension · Oral use | 1 Bottle | SAR 51.20 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| CLARITT 250 MG FILM COATED | 250 mg | Extended-release tablet · Oral use | 14 Blister | SAR 46.90 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| CLARITT 500 MG FILM COATED TAB | 500 mg | Film-coated tablet · Oral use | 14 Blister | SAR 70.00 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| CLARITT XL 500 MG EXTENDED RELEASE TAB. | 500 mg | Extended-release tablet · Oral use | 7 Blister | SAR 48.80 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| CLARITT XL 500MG EXTENDED RELEASE TABLETS | 500 mg | Extended-release tablet · Oral use | 14 Blister | SAR 72.00 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| CLARIXIN 500 MG TABLET | 500 mg | Film-coated tablet · Oral use | 14 Blister | SAR 51.15 | Generic · Prescription | Med City Pharma | Valid |
| CLERON 250MG F.C.TABLET | 250 mg | Film-coated tablet · Oral use | 14 Blister | SAR 22.00 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| CLERON 500MG F.C.TABLET | 500 mg | Film-coated tablet · Oral use | 14 Blister | SAR 32.50 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| EMIMYCIN 500 MG TABLETS | 500 mg | Film-coated tablet · Oral use | 14 Blister | SAR 40.10 | Generic · Prescription | GLOBAL PHARMA | Valid |
| ERACID 250MG TABLET | 250 mg | Film-coated tablet · Oral use | 14 Blister | SAR 19.35 | Generic · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Valid |
| ERACID 500MG FILM COATED TABLETS | 500 mg | Film-coated tablet · Oral use | 14 Blister | SAR 37.30 | Generic · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Valid |
| KLACID 125MG-5ML SUSP | 25 mg/ml | Granules for suspension · Oral use | 1 Bottle | SAR 27.95 | NCE · Prescription | Abbott Laboratories Limited | Valid |
| KLACID 125MG-5ML SUSP | 25 mg/ml | Oral suspension · Oral use | 100 Bottle | SAR 46.60 | NCE · Prescription | Abbott Laboratories Limited | Valid |
| KLACID 250MG TAB | 250 mg | Tablet · Oral use | 14 Blister | SAR 60.40 | NCE · Prescription | Abbott Laboratories GmbH | Valid |
| KLACID 500MG COATED TAB | 500 mg | Coated tablet · Oral use | 14 Blister | SAR 90.20 | NCE · Prescription | Abbott Laboratories | Valid |
| KLACID 500MG IV POWDER FOR INJECTION | 500 mg | Powder for injection · Intravenous use | 1 Vial | SAR 54.90 | NCE · Prescription | Abbott Laboratories Limited | Valid |
| KLACID XL 500MG TAB | 500 mg | Extended-release tablet · Oral use | 14 Blister | SAR 85.95 | Generic · Prescription | Abbott Laboratories | Valid |
19 more — full table
Indications — CHI Daman Drug Formulary
ACUTE COUGH; ACUTE EXACERBATION OF BRONCHIECTASIS (NON-CYSTIC FIBROSIS); ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD); BACTERIAL SKIN INFECTIONS - ERYSIPELAS AND CELLULITIS; BACTERIAL SKIN INFECTIONS - IMPETIGO AND ECTHYMA; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT- H-PYLORI ERADICATION-EVIDENCE BASED FIRST LINE TREATMENT STRATEGY; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT- H-PYLORI ERADICATION-SALVAGE THERAPIES; COMMUNITY ACQUIRED PNEUMONEA; DENTAL ABSCESS; ENDOCARDITIS; HOSPITAL AND VENTILATER ACQUIRED PNEUMONIA; HUMAN IMMUNODEFICIENCY VIRUS; MARGINAL ZONE LYMPHOMA; OTITIS MEDIA; PERICORONITIS; PHARYNGITIS; SINUSITIS; TRAVEL RELATED INFECTIONS-TREATMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CLARITHROMYCIN | 500MG | tablet, extended release · oral | ACTAVIS LABS FL INC | Prescription | 24 Jun 2004 |
| CLARITHROMYCIN | 500MG | tablet, extended release · oral | DR REDDYS LABS SA | Prescription | 18 May 2005 |
| CLARITHROMYCIN | 500MG | tablet · oral | SANDOZ | Prescription | 25 Aug 2005 |
| CLARITHROMYCIN | 250MG | tablet · oral | SANDOZ | Prescription | 18 Oct 2005 |
| CLARITHROMYCIN | 250MG; 500MG | tablet · oral | CHARTWELL | Prescription | 20 Aug 2007 |
| CLARITHROMYCIN | 125MG/5ML; 250MG/5ML | for suspension · oral | SANDOZ | Prescription | 4 Sep 2007 |
| CLARITHROMYCIN | 250MG; 500MG | tablet · oral | AUROBINDO | Prescription | 25 Jul 2012 |
| CLARITHROMYCIN | 250MG; 500MG | tablet · oral | NOVITIUM PHARMA | Prescription | 10 Jun 2013 |
| CLARITHROMYCIN | 250MG; 500MG | tablet · oral | HEC PHARM | Prescription | 28 Sep 2015 |
| CLARITHROMYCIN | 500MG | tablet, extended release · oral | MPP PHARMA | Prescription | 29 Feb 2016 |
| CLARITHROMYCIN | 500MG | tablet, extended release · oral | SUNSHINE | Prescription | 9 Jul 2018 |
| CLARITHROMYCIN | 250MG; 500MG | tablet · oral | ALEMBIC | Prescription | 31 Jan 2022 |
| BIAXIN | 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | ABBVIE | Discontinued | 31 Oct 1991 |
| BIAXIN XL | 250MG; 500MG | tablet · oral | ABBVIE INC | Discontinued | 23 Dec 1993 |
| BIAXIN | 125MG/5ML; 250MG/5ML; 187MG/5ML | for suspension · oral | ABBVIE | Discontinued | 23 Dec 1993 |
| BIAXIN XL | 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, extended release · oral | ABBVIE | Discontinued | 3 Mar 2000 |
| CLARITHROMYCIN | 500MG; 250MG | tablet · oral | HIKMA PHARMS | Discontinued | 25 May 2004 |
| CLARITHROMYCIN | 250MG; 500MG | tablet · oral | SUN PHARM INDS LTD | Discontinued | 24 Sep 2004 |
| CLARITHROMYCIN | 1GM | tablet, extended release · oral | RANBAXY | Discontinued | 26 Jan 2005 |
| CLARITHROMYCIN | 250MG; 500MG | tablet · oral | PHARMOBEDIENT | Discontinued | 11 Mar 2005 |
| CLARITHROMYCIN | 250MG; 500MG | tablet · oral | IVAX SUB TEVA PHARMS | Discontinued | 31 May 2005 |
| CLARITHROMYCIN | 250MG; 500MG | tablet · oral | TEVA | Discontinued | 31 May 2005 |
| CLARITHROMYCIN | 500MG | tablet, extended release · oral | ANI PHARMS | Discontinued | 25 Aug 2005 |
| CLARITHROMYCIN | 250MG; 500MG | tablet · oral | WOCKHARDT | Discontinued | 31 May 2006 |
| CLARITHROMYCIN | 125MG/5ML; 250MG/5ML | for suspension · oral | SUN PHARM INDS LTD | Discontinued | 30 Aug 2007 |
2 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-CLARITHROMYCIN | 02274744 | 250 MG | TABLET · ORAL | APOTEX INC |
| APO-CLARITHROMYCIN | 02274752 | 500 MG | TABLET · ORAL | APOTEX INC |
| APO-CLARITHROMYCIN XL | 02413345 | 500 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| BIAXIN | 02146908 | 125 MG / 5 ML | GRANULES FOR SUSPENSION · ORAL | BGP PHARMA ULC |
| BIAXIN | 02244641 | 250 MG / 5 ML | GRANULES FOR SUSPENSION · ORAL | BGP PHARMA ULC |
| BIAXIN BID | 01984853 | 250 MG | TABLET · ORAL | BGP PHARMA ULC |
| BIAXIN BID | 02126710 | 500 MG | TABLET · ORAL | BGP PHARMA ULC |
| CLARITHROMYCIN | 02442469 | 250 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CLARITHROMYCIN | 02442485 | 500 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CLARITHROMYCIN | 02466120 | 250 MG | TABLET · ORAL | SANIS HEALTH INC |
| CLARITHROMYCIN | 02466139 | 500 MG | TABLET · ORAL | SANIS HEALTH INC |
| M-CLARITHROMYCIN | 02471396 | 500 MG | TABLET · ORAL | MANTRA PHARMA INC |
| PRO-CLARITHROMYCIN | 02324482 | 250 MG | TABLET · ORAL | PRO DOC LIMITEE |
| PRO-CLARITHROMYCIN | 02324490 | 500 MG | TABLET · ORAL | PRO DOC LIMITEE |
| SANDOZ CLARITHROMYCIN | 02266539 | 250 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ CLARITHROMYCIN | 02266547 | 500 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| TARO-CLARITHROMYCIN | 02361426 | 250 MG | TABLET · ORAL | SUN PHARMA CANADA INC |
| TARO-CLARITHROMYCIN | 02361434 | 500 MG | TABLET · ORAL | SUN PHARMA CANADA INC |
| TARO-CLARITHROMYCIN | 02390442 | 125 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | TARO PHARMACEUTICALS INC |
| TARO-CLARITHROMYCIN | 02390450 | 250 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | TARO PHARMACEUTICALS INC |
| TEVA-CLARITHROMYCIN XL | 02403196 | 500 MG | TABLET (EXTENDED-RELEASE) · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CLARITHROMYCIN 125 MG/5 ML SUS | $0.93931 | per ML | 23 Sep 2026 |
| US NADAC | CLARITHROMYCIN 250 MG TABLET | $0.39391 | per EA | 23 Sep 2026 |
| US NADAC | CLARITHROMYCIN 250 MG/5 ML SUS | $1.34544 | per ML | 23 Sep 2026 |
| US NADAC | CLARITHROMYCIN 250 MG/5 ML SUS | $1.56592 | per ML | 23 Sep 2026 |
| US NADAC | CLARITHROMYCIN 500 MG TABLET | $0.46583 | per EA | 23 Sep 2026 |
| US NADAC | CLARITHROMYCIN ER 500 MG TAB | $1.91822 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Clarithromycin 125mg/5ml oral suspension | £12.10 | 70 ml | 1 Oct 2026 |
| NHS Drug Tariff | Clarithromycin 250mg tablets | £1.03 | 14 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Clarithromycin 250mg/5ml oral suspension | £24.84 | 70 ml | 1 Oct 2026 |
| NHS Drug Tariff | Clarithromycin 500mg modified-release tablets | £6.72 | 7 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Clarithromycin 500mg modified-release tablets | £13.23 | 14 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Clarithromycin 500mg tablets | £1.92 | 14 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.2. Watch group antibiotics · core
First choice: Bacterial pneumonia (Community-acquired pneumonia - severe) (co-prescribed with cefotaxime); First choice: Bacterial pneumonia (Community-acquired pneumonia - severe) (co-prescribed with ceftriaxone); Second choice: Acute pharyngitis; Second choice: Bacterial pneumonia (Community-acquired pneumonia - severe) (co-prescribed with amoxicillin + clavulanic acid); Helicobacter pylori associated gastric ulcer
Oral > Liquid: 125 mg per 5 mL powder for oral liquid (EML); 250 mg per 5 mL powder for oral liquid (EML) | Parenteral > General injections > unspecified: 500 mg in vial powder for injection (EML) | Oral > Solid > dosage form: 500 mg (EML) | Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid | Parenteral > General injections > unspecified: 500 mg in vial powder for injection | Oral > Solid > dosage form: 500 mg (EML); 250 mg (EMLc) | Oral > Solid > dosage form: 500 mg
Safety signals and safety-related labeling changes
- US FDA 31 Oct 2025 VOQUEZNA TRIPLE PAK — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 1 May 2024 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Sep 2019 BIAXIN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Sep 2019 BIAXIN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Sep 2019 BIAXIN XL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 7 Jun 2018 PREVPAC — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 29 Sep 2017 PRAC signal: Acute generalised exanthematous pustulosis (AGEP)
Action for MAH: update of the product information: Yes - EMA PRAC 5 May 2017 PRAC signal: Acute generalised exanthematous pustulosis (AGEP)
Action for MAH: update of the product information: No - EMA PRAC 10 Oct 2013 PRAC signal: Cardiovascular events
Action for MAH: update of the product information: No - EMA PRAC 16 May 2013 PRAC signal: Cardiovascular events
Action for MAH: update of the product information: No
Combinations containing Clarithromycin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.